Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 10/20 | 0.40 |
| ▸ | RAB9A | P51151 | 10/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | MEN1 | O00255 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | PKM | P14618 | 4/20 | 0.40 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 7/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.37 |
| ▸ | PI4KA | P42356 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL549303 | 0.88 | SNCA (0.52) | SNCANPC1RAB9AKMT2AKDM4E | |
| SCHEMBL548460 | 0.82 | KDM4E (0.35) | NPC1RAB9AKMT2AKDM4EMEN1 | |
| SCHEMBL549175 | 0.81 | POLB (0.35) | SNCANPC1RAB9AKMT2AKDM4E | |
| SCHEMBL549263 | 0.78 | NISCH (0.41) | SNCANPC1RAB9AKMT2AKDM4E | |
| SCHEMBL549262 | 0.78 | NISCH (0.41) | SNCANPC1RAB9AKMT2AKDM4E | |
| SCHEMBL5306795 | 0.76 | RAB9A (0.48) | NPC1RAB9AKMT2AKDM4EMEN1 | |
| SCHEMBL548445 | 0.75 | RAB9A (0.45) | NPC1RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL548491 | 0.75 | F10 (0.43) | NPC1RAB9ASMN1; SMN2PKMMAPT | |
| SCHEMBL549230 | 0.75 | NPC1 (0.37) | NPC1RAB9AKMT2AKDM4EMEN1 | |
| SCHEMBL3835605 | 0.73 | KDM4E (0.38) | NPC1RAB9AKMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | BORISY ALEXIS | 2007-05-03 | — | — | US | claimed |
| EP-1651211-A4 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX INC (US) | 2006-11-22 | — | — | EP | claimed |
| CN-1829509-A | Pharmaceutical composition for treating tumors | COMBINATORX INC (US) | 2006-09-06 | — | — | CN | claimed |
| EP-1651211-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | Combinatorx, Incorporated (US) | 2006-05-03 | — | — | EP | claimed |
| CN-1681511-A | Combinations of drugs for the treatment of neoplasms | COMBINATORX INC (US) | 2005-10-12 | — | — | CN | claimed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | claimed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | claimed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | claimed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | claimed |
| EP-1891013-B1 | TETRAHYDROQUINOLINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8524732-B2 | Substituted tetrahydroquinolines | MERCK PATENT GMBH (DE) | 2013-09-03 | — | — | US | disclosed |
| EP-2121700-B1 | SUBSTITUTED TETRAHYDROQUINOLINES | MERCK PATENT GMBH (DE) | 2012-10-03 | — | — | EP | disclosed |
| US-8207345-B2 | Antitumor agents; use in combination with other drugs such as pentamidine | MERCK PATENT GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | FINSINGER DIRK (DE) | 2012-05-24 | — | — | US | disclosed |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2005-04-14 | — | — | US | disclosed |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | COMINATORX, INCORPORATED | 2005-03-10 | — | — | US | disclosed |
| WO-2005011572-A2 | COMBINATION OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2005-02-10 | — | — | WO | disclosed |
| US-20040116407-A1 | Combinations of drugs for the treatment of neoplasms | COMBINATORX, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2004006842-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004006849-A2 | COMBINATIONS OF DRUGS FOR THE TREATMENT OF NEOPLASMS | COMBINATORX, INCORPORATED (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120130147-A1 | METHODS FOR THE TREATMENT OF TUMORS WITH INDANE COMPOUNDS | TP53, IDH3A, IDH2 | SNCA 1829/4885NPC1 735/4885RAB9A 2433/4885 |
| US-20050080075-A1 | Formulations, conjugates, and combinations of drugs for the treatment of neoplasms | ABCB1, SLCO1B3, SLCO1B1 | SNCA 1276/4885NPC1 280/4885RAB9A 1496/4885 |
| US-20070099905-A1 | Combinations of drugs for the treatment of neoplasms | VHL, NRAS, MYC | SNCA 2399/4885NPC1 917/4885RAB9A 4125/4885 |
| US-20050054708-A1 | Combinations of drugs for the treatment of neoplasms | TYMP, DPYD, DHFR | SNCA 1950/4885NPC1 3162/4885RAB9A 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.